Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation | Zendy

Hugh Calkins | Zendy; Stephan Willems | Zendy; Edward P. Gerstenfeld | Zendy; Atul Kumar | Zendy; Richard J. Schilling | Zendy; Stefan H. Hohnloser | Zendy; Ken Okumura | Zendy; Harvey Serota | Zendy; Matias Nordaby | Zendy; Kelly Guiver | Zendy; Branislav Biss | Zendy; Marc A. Brouwer | Zendy; Massimo Grimaldi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation

Author(s) -

Hugh Calkins,

Stephan Willems,

Edward P. Gerstenfeld,

Atul Kumar,

Richard J. Schilling,

Stefan H. Hohnloser,

Ken Okumura,

Harvey Serota,

Matias Nordaby,

Kelly Guiver,

Branislav Biss,

Marc A. Brouwer,

Massimo Grimaldi

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1701005

Subject(s) - medicine , dabigatran , vitamin k antagonist , warfarin , atrial fibrillation , oral anticoagulant , catheter ablation , ablation , anesthesia , cardiology , anticoagulant , vitamin k epoxide reductase , antagonist , receptor , cyp2c9 , cytochrome p450 , metabolism

Catheter ablation of atrial fibrillation is typically performed with uninterrupted anticoagulation with warfarin or interrupted non-vitamin K antagonist oral anticoagulant therapy. Uninterrupted anticoagulation with a non-vitamin K antagonist oral anticoagulant, such as dabigatran, may be safer; however, controlled data are lacking. We investigated the safety of uninterrupted dabigatran versus warfarin in patients undergoing ablation of atrial fibrillation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research